These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37045504)

  • 21. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
    Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
    Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention.
    Zhang M; Wang J; Zhang Y; Zhang P; Chao Y; Gao M; Hou Y
    Perfusion; 2022 Jan; 37(1):78-85. PubMed ID: 33300437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Impact of
    Kim JH; Lee SJ; Cha JJ; Park JH; Hong SJ; Ahn TH; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Jeong YH; Kim HS; Kim MH; Shin ES; Lim DS;
    J Am Heart Assoc; 2024 May; 13(10):e032248. PubMed ID: 38761068
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Beitelshees AL; Thomas CD; Empey PE; Stouffer GA; Angiolillo DJ; Franchi F; Tuteja S; Limdi NA; Lee JC; Duarte JD; Kreutz RP; Skaar TC; Coons JC; Giri J; McDonough CW; Rowland R; Stevenson JM; Thai T; Vesely MR; Wellen JT; Johnson JA; Winterstein AG; Cavallari LH; Lee CR;
    J Am Heart Assoc; 2022 Feb; 11(4):e024159. PubMed ID: 35156424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
    Watanabe H; Morimoto T; Ogita M; Suwa S; Natsuaki M; Suematsu N; Koeda Y; Morino Y; Nikaido A; Hata Y; Doi M; Hibi K; Kimura K; Yoda S; Kaneko T; Nishida K; Kawai K; Yamaguchi K; Wakatsuki T; Tonoike N; Yamamoto M; Shimizu S; Shimohama T; Ako J; Kimura T;
    Cardiovasc Interv Ther; 2021 Oct; 36(4):403-415. PubMed ID: 33184726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
    Cavallari LH; Franchi F; Rollini F; Been L; Rivas A; Agarwal M; Smith DM; Newsom K; Gong Y; Elsey AR; Starostik P; Johnson JA; Angiolillo DJ
    J Transl Med; 2018 Apr; 16(1):92. PubMed ID: 29642909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
    Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G;
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
    Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
    J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
    Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS
    JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2C19 genotype-directed P
    Stys TP; Gedela M; Gowda SN; Bares V; Fanta L; Petrasko M; Hajek C; Larson E; Stys AT
    Indian Heart J; 2021; 73(3):281-288. PubMed ID: 34154743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium.
    Jeon KH; Jeong YH; Chae IH; Kim BK; Joo HJ; Chang K; Park Y; Song YB; Ahn SG; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Suh JW;
    Cardiovasc Diabetol; 2023 Sep; 22(1):245. PubMed ID: 37679760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
    Tan DS; Aw JWX; Winther M; Goh LL; Ong HY; Wee E; Liu J; Ho HK
    J Clin Pharm Ther; 2020 Feb; 45(1):52-58. PubMed ID: 31670842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.